# A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors

> **NCT07897721** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Pfizer** · enrollment: 268 (estimated)

## Conditions studied

- Advanced Breast Cancer
- Advanced or Metastatic Breast Cancer
- Metastatic Breast Cancer (HR+/ HER2-)
- Metastatic Colorectal Adenocarcinoma

## Interventions

- **DRUG:** PF-08165784
- **DRUG:** Fulvestrant
- **DRUG:** Atirmociclib
- **DRUG:** Cetuximab
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT07897721
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11-09
- **Primary completion:** 2030-03-22
- **Final completion:** 2032-03-21
- **Target enrollment:** 268 (ESTIMATED)
- **Last updated:** 2026-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07897721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07897721, "A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors". Retrieved via MORVS 2026-11-22 from https://api.morvs.ai/clinical/NCT07897721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*
